Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219297 · ClinicalTrials.gov registry record · Phase 2
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00219297 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT00219297, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after chemotherapy, surgery and/or radiation.
Interventions
- DRUG Patupilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-11-16 |
| Est. Completion | 2010-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219297
The ClinicalTrials.gov registry entry for NCT00219297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patupilone is the first listed.
NCT00219297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219297 about?
NCT00219297 is a clinical study titled "Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer". The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after chemotherapy, surgery and/or radiation.
What is the current status of trial NCT00219297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-11-16. Estimated completion is 2010-06-24.
What interventions are being tested in trial NCT00219297?
The interventions under investigation include: Patupilone (DRUG).
Who is sponsoring clinical trial NCT00219297?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.